Investigating the course of atopic eczema up to 1 year following completion of Narrowband UVB (NBUVB) phototherapy
Clinical and Experimental Dermatology · 2026
DOI: 10.1093/ced/llag066 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Sonali Bajaj und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital of North Durham, County Durham and Darlington NHS Foundation Trust, Darlington, Durham, UK. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Ultraviolet Therapy. Gefördert von: British Skin Foundation.
Abstract (Originalsprache)
Background
Narrowband UVB (NBUVB) is a second-line treatment for chronic moderate-to-severe atopic eczema unresponsive to adequate topical therapy, and is known to induce good short-term improvement of eczema severity. However, it is unclear how adult patients fare with their eczema severity long after completion of a course of NBUVB.
Objectives
We aimed to investigate the severity of atopic eczema in adults, 1 year following completion of NBUVB, using validated clinical activity measures.
Methods
We undertook a multi-centre prospective observational study of adults with moderate-to-severe atopic eczema who were prescribed NBUVB as part of their standard clinical care. Assessments were made at baseline prior to starting NBUVB, at the end of NBUVB and at 4, 8 and 12 months after completion of NBUVB.
Results
Eighty participants with moderate-to-severe atopic eczema (mean SCORAD 39.2, POEM 18.5, IGA 3.2) underwent NBUVB therapy. Significant reductions were observed post-treatment: SCORAD decreased to 17.8, POEM to 8.2, and IGA to 1.7 (p<0.001 achieved for all time points). These therapeutic effects were sustained at 4, 8, and 12 months post-treatment (n=27 at 12 months). Loss of follow-up was attributed to non-attendance exacerbated by the COVID-19 pandemic and patient relocation. Mild adverse events (n=5), including erythema and eczema flares, were reported, with no serious events.
Conclusions
These findings indicate that NBUVB may provide a long-lasting effect for patients who complete a course, helping to diminish their eczema severity to a more manageable level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Dermatology, University Hospital of North Durham, County Durham and Darlington NHS Foundation Trust, Darlington, Durham, UK.
- Durham University, Durham, UK.
- Department of Dermatology, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, UK.
Förderung
- British Skin Foundation
Zitieren
APA
Bajaj, S., Desai, P., Singh, A., Jain, D., & Wahie, S. (2026). Investigating the course of atopic eczema up to 1 year following completion of Narrowband UVB (NBUVB) phototherapy. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag066
Vancouver
Bajaj S, Desai P, Singh A, Jain D, Wahie S. Investigating the course of atopic eczema up to 1 year following completion of Narrowband UVB (NBUVB) phototherapy. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag066
BibTeX
@article{Bajaj2026,
author = {Bajaj, Sonali and Desai, Prachi and Singh, Akansha and Jain, Dimple and Wahie, Shyamal},
title = {Investigating the course of atopic eczema up to 1 year following completion of Narrowband UVB (NBUVB) phototherapy},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llag066}
}
EUVIMED